Oncology Clinical Trials in Fort Myers, FL

As of July 2026, 64 paid clinical trials are recruiting for Oncology in Fort Myers, Florida. Oncology trials evaluate immunotherapies, targeted therapies, antibody-drug conjugates, and combination regimens across solid tumors and blood cancers — from early-phase first-in-human studies to phase 3 registration trials. Compensation typically covers time, travel, and study visits, and many studies also include study-related medical care at no cost.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 13, 2026.

Filter results

Filter results

State

City

Facility

Phase

Study type

Intervention

Recruitment status

Condition

Sex

Age

Healthy volunteers only

64 clinical trials for Oncology

·Clear filters·↓ Download CSV

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

for Acute Lymphoblastic Leukemia

745 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 40 - 75·Accepts healthy volunteers

Code: NCT05334069·Recruiting

Apply to this trial

Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors

for Hodgkin Lymphoma

428 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT06002828·Recruiting

Apply to this trial

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

for Lymphoma, Non-Hodgkin

174 locations incl. Birmingham

Sponsor: American Society of Clinical Oncology

Sex: All·Age: 12+

Code: NCT02693535·Phase 2·Recruiting

Apply to this trial

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

for Ovarian Carcinoma

539 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Female·Age: 35 - 50

Code: NCT04251052·Recruiting

Apply to this trial

Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer

for Hematopoietic and Lymphatic System Neoplasm

190 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: Female·Age: Up to 39

Code: NCT06513962·Phase 3·Recruiting

Apply to this trial

Project: Every Child for Younger Patients With Cancer

for Adrenal Gland Pheochromocytoma

245 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 25

Code: NCT02402244·Recruiting

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

203 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

185 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

164 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting

Apply to this trial

Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma

for Metastatic Malignant Neoplasm in the Lung

219 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 50

Code: NCT05235165·Phase 3·Recruiting

Apply to this trial

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

for Ganglioneuroblastoma

152 locations incl. Madison

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 30

Code: NCT03126916·Phase 3·Recruiting

Apply to this trial

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

for Ganglioneuroblastoma, Nodular

156 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 30

Code: NCT06172296·Phase 3·Recruiting

Apply to this trial

A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study

for Hematopoietic and Lymphatic System Neoplasm

76 locations incl. Mesa

Sponsor: Children's Oncology Group

Sex: All·Age: 15 - 20

Code: NCT06410209·Phase 2·Recruiting

Apply to this trial

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

for Acute Myeloid Leukemia

Drug: Venetoclax

45 locations incl. Phoenix

Sponsor: PedAL BCU, LLC

Sex: All·Age: 29 Days - 21

Code: NCT05183035·Phase 3·Recruiting

Apply to this trial

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

for Hodgkin Lymphoma in Remission

69 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT01790152·Recruiting

Apply to this trial

Registry Study for Radiation Therapy Outcomes

for Neoplasms

29 locations incl. Scottsdale

Sponsor: Proton Collaborative Group

Sex: All·Age: All ages

Code: NCT01255748·Recruiting

Apply to this trial

Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma

for Follicular Lymphoma

Drug: Rituximab

5 locations incl. Fort Myers

Sponsor: Juan P. Alderuccio, MD

Sex: All·Age: 18+

Code: NCT04998669·Phase 2·Recruiting

Apply to this trial

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

for Multiple Myeloma

Drug: Belantamab mafodotin

9 locations incl. Los Alamitos

Sponsor: GlaxoSmithKline

Sex: All·Age: 18+

Code: NCT07227311·Phase 2·Recruiting

Apply to this trial

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

for Gastric Cancer

Drug: Sonesitatug vedotin

83 locations incl. Mobile

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07431281·Phase 3·Recruiting

Apply to this trial

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for Non-small Cell Lung Cancer (NSCLC)

50 locations incl. Chandler

Sponsor: AstraZeneca

Sex: All·Age: 18+

Code: NCT07291037·Phase 3·Recruiting

Apply to this trial

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

for Endometrial Cancer

Drug: Rilvegostomig

60 locations incl. Tucson

Sponsor: AstraZeneca

Sex: Female·Age: 18+

Code: NCT06989112·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

37 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06525220·Phase 3·Recruiting

Apply to this trial

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

for Biliary Tract Cancer

Drug: Rilvegostomig

48 locations incl. Scottsdale

Sponsor: AstraZeneca

Sex: All·Age: 18 - 99

Code: NCT06467357·Phase 3·Recruiting

Apply to this trial

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)

for Head and Neck Squamous Cell Carcinoma

Drug: Petosemtamab

61 locations incl. Mobile

Sponsor: Merus B.V.

Sex: All·Age: 18+

Code: NCT06496178·Phase 3·Recruiting

Apply to this trial

Conditions in Oncology (Fort Myers, FL)

Non-small cell lung cancer (NSCLC)· 14 Solid tumor· 10 Breast cancer· 8 Endometrial cancer· 6 Colorectal cancer· 5 Ovarian cancer· 5 Cancer (any)· 5 Gastric cancer· 4 Esophageal cancer· 4 Acute myeloid leukemia (AML)· 4 Chronic lymphocytic leukemia (CLL)· 4 Gastroesophageal junction cancer· 3 Fallopian tube cancer· 3 Multiple myeloma· 3 Hematologic malignancy· 3 Head and neck cancer· 3 Pancreatic cancer· 2 Bladder cancer· 2 Acute lymphoblastic leukemia· 2 Leukemia (other)· 2 Non-Hodgkin lymphoma· 2 Small lymphocytic lymphoma· 2 Osteosarcoma· 2 Neuroblastoma· 2 Metastatic breast cancer· 1 Triple-negative breast cancer· 1 Lung cancer· 1 Metastatic colorectal cancer· 1 Biliary tract cancer· 1 Cervical cancer· 1 Uterine cancer· 1 Myelodysplastic syndromes (MDS)· 1 Myeloproliferative neoplasm· 1 Hodgkin lymphoma· 1 Follicular lymphoma· 1 Melanoma· 1 Sarcoma· 1 Mesothelioma· 1